HCPCS Level II code C9360 identifies a native, non-denatured neonatal bovine collagen dermal substitute (Surgimend collagen matrix) billed per 0.5 square centimeters. This code matters nationally as use of biologic dermal matrices has grown in reconstructive surgery, burn care, and complex wound management, affecting hospital supply costs and payer coverage policies. The code enables itemized reporting of biologic matrix products distinct from grafts or synthetic substitutes.

Key payers addressed include Aetna, Blue Cross Blue Shield, Cigna, UnitedHealthcare, and Medicare. Readers will find a concise clinical context for the material and where it is typically applied, together with coverage and billing considerations relevant to these major payers. The publication covers expected benchmarks for coding and claims submission practice, common modifiers associated with surgical supply billing, and policy developments that influence reimbursement and utilization management for dermal substitutes.

The content outlines the clinical role of the product in supporting dermal regeneration, typical sites of service such as hospital operating rooms and outpatient surgical centers, and practical billing information for clinicians and coding professionals. Data not provided in the input—such as associated taxonomies, specific ICD-10 indications, payer-specific payment rates, and related codes—is noted where applicable.